TY  - JOUR
AU  - Brener, Oleksandr
AU  - Dunkelmann, Tina
AU  - Gremer, Lothar
AU  - van Groen, Thomas
AU  - Mirecka, Ewa A.
AU  - Kadish, Inga
AU  - Willuweit, Antje
AU  - Kutzsche, Janine
AU  - Jürgens, Dagmar
AU  - Rudolph, Stephan
AU  - Tusche, Markus
AU  - Bongen, Patrick
AU  - Pietruszka, Jörg
AU  - Oesterhelt, Filipp
AU  - Langen, Karl-Josef
AU  - Demuth, Hans-Ulrich
AU  - Janssen, Arnold
AU  - Hoyer, Wolfgang
AU  - Funke, Susanne A.
AU  - Nagel-Steger, Luitgard
AU  - Willbold, Dieter
TI  - QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers
JO  - Scientific reports
VL  - 5
SN  - 2045-2322
CY  - London
PB  - Nature Publishing Group
M1  - FZJ-2015-06933
SP  - 13222
PY  - 2015
AB  - Strong evidence exists for a central role of amyloid β-protein (Aβ) oligomers in the pathogenesis of Alzheimer’s disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, to quantify the effect of any compound on the Aβ aggregate size distribution. Applying QIAD, we studied the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZAβ3W, the D-enantiomeric peptide D3 and its tandem version D3D3 on Aβ aggregation. The predictive power of the assay for in vivo efficacy is demonstrated by comparing the oligomer elimination efficiency of D3 and D3D3 with their treatment effects in animal models of Alzheimer´s disease.
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000361591400001
C6  - pmid:26394756
DO  - DOI:10.1038/srep13222
UR  - https://juser.fz-juelich.de/record/276568
ER  -